Vertex Pharmaceuticals

• 8-KCEO/CFO change

  Filed Sep 1

  Jonathan Poole takes over as CFO on Jan. 1, 2027; Charles F. Wagner remains EVP and COO.

• 10-QQ2 FY2026Positive

  Filed Aug 4

  Pending Crinetics deal expands the push into endocrinology as JOURNAVX launch spending and product costs squeeze margins.

  • Revenue$3.3BYoY +12.5%
  • Net income$1.1BYoY +6.5%

• 8-KPositiveEarningsGuidance raised

  Filed Aug 3

  Cystic fibrosis, CASGEVY and JOURNAVX growth underpin a raised revenue outlook ahead of the planned Crinetics acquisition.

• 8-KPositiveDeal pendingDebt financing

  Filed Jul 6

  Planned Crinetics acquisition targets PALSONIFY and atumelnant’s more than $5B in potential annual peak revenue.

Coverage: 10-K, 10-Q and 8-K filings filed since Jul 1, 2026.

Request longer coverage

Company data: Wikidata Q2744099